CREATE Opportunities Act

H.R. 3591: Campus Prevention and Recovery Services for Students Act of 2019 H.R. 2466: State Opioid Response Grant Authorization Act H.R. 2922: Respond Now Act H.R. 3489, S. 1204: Higher Education Mental Health Act of 2019 H.R. 3496, S. 1983: Create Opportunities Act H.R. 2569, S. 1365: Comprehensive Addiction Resources Emergency Act

Client expense: $320,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Natl Science Foundation (NSF), Natl Security Agency (NSA), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)

Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) HR 7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021 HR 7614 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2021 HR 7612 - Interior, Environment, and Related Agencies Appropriations Act, 2021 Department of Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021

Client expense: $730,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)

Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020 (H.R. 2740); CREATE Opportunities Act (S. 1983); Families First Coronavirus Response Act (H.R. 6201); Coronavirus Aid, Relief and Economic Security Act (H.R. 748); Issues related to emergency supplemental funding for behavioral health organizations.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), all provisions related to relief funding, telehealth, and Medicare in response to the novel, COVID-19 pandemic. The Families First Coronavirus Response Act (H.R. 6201), all provisions related to relief funding, Medicaid, and paid leave in response to the novel, COVID-19 pandemic. The Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748), all provisions related to relief funding in response to the novel, COVID-19 pandemic. The Special Registration for Telemedicine Clarification Act (H.R. 5483 (115)), all provisions related to establishing a special registration process with the Drug Enforcement Agency (DEA) for certain providers that wish to prescribe controlled substances via telemedicine. Mainstreaming Addiction Treatment Act (S. 2074/H.R. 2482), all provisions related to removing the waiver requirement for health care providers to prescribe buprenorphine for opioid use disorder. National Suicide Hotline Designation Act of 2019 (H.R. 4194), all provisions related to requiring the Federal Communications Commission designate 9-8-8 as a universal national suicide prevention and mental health crisis hotline number. Improving Access to Remote Behavioral Health Treatment Act of 2019 (S. 2244/H.R. 4131), all provisions related to amending regulations for the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 and allowing community mental health centers to register to practice telemedicine. Comprehensive Addiction Resources Emergency Act of 2019 (S. 1365/H.R. 2569), all provisions related to providing emergency assistance to areas affected by the opioid epidemic, as well as grant funding for substance use disorder treatment research. Medication Access and Training Expansion Act of 2019 (H.R. 4974), all provisions related to prescriber training on treating patients with opioid and other substance use disorders. Resilience Investment, Support and Expansion from Trauma Act (S. 1770/H.R. 3180), all provisions related to supporting children and families who experience trauma. CREATE Opportunities Act (S. 1983/H.R. 3496), all provisions related to providing medication-assisted treatment to individuals with opioid use disorder and are incarcerated. Primary and Behavioral Health Care Access Act (H.R. 5575), all provisions related to requiring group health plans and health insurance issuers to provide for primary and behavioral health care visits without cost-sharing. Ensuring Patient Access to Critical Breakthrough Products Act of 2019 (H.R. 5333), all provisions related to ensuring prompt coverage of breakthrough devices under the Medicare program.

The Crisis Stabilization and Community Reentry Act (S. 3312/H.R. 5909), all provisions related to establishing a grant program for justice agencies and community-based behavioral health providers, as well as a technical assistance center. Medicaid Reentry Act (H.R. 1329), all provisions related to allowing Medicaid coverage for eligible incarcerated individuals to be re-established up to 30 days before their release from jail or prison. National De-Escalation of Violence and Community Safety Training Act (H.R. 2457), all provisions related to establishing a program allowing eligible entities such as churches, schools, community colleges, or state and local governments to provide de-escalation training to prevent and reduce violence in our communities, including the reauthorization of Mental Health First Aid training grants. CREATE Opportunities Act (S. 1983/H.R. 3496), all provisions related to expanding medication-assisted treatment for incarcerated individuals. Restoring, Enhancing, Securing, and Promoting Our Nations Safety Efforts (RESPONSE) Act of 2019 (S. 2690), all provisions related to strengthening mental health collaboration in communities.

Client expense: $125,180 · Firm income: Not reported

Issues surrounding cleanup standards for soil remediation at superfund sites and policies for encouraging faster clean up of superfund sites. Issues regarding use of ethylene oxide. Clean Industrial Technology Act (H.R. 3978, H.R. 4230, S. 2300). BASF supports CITA as a step to addressing climate change, by encouragint the development and evaluation of innovative technologies aimed at increasing the technological and economic competitiveness of industry and manufacturing in the US and increasing emissions reductions in non-power industrial sectors. Climate Change (no bills). BASF supports legislation on climate change that: ensure that reduction targets are economically feasible and technologically reasonable. Policies must allow energy-intensive and trade-exposed (EITE) companies to remain globally competitive (carbon leakage protection). Plastics, S. 1983, H.R. 5115, S. 2941: Save Our Seas Act 2.0 (BASF supports the bill and proposals for funding of advanced recylcling

Client expense: $330,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE

Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94)

Client expense: $1,170,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)

HR 3591 Campus Prevention and Recovery Services for Students Act of 2019 HR 2466 State Opioid Response Grant Authorization Act HR 2922 Respond Now Act HR 3849, S. 1204 Higher Education Mental Health Act of 2019 HR 3496, S. 1983 Create Opportunities Act HR 2569, S. 1365 Comprehensive Addiction Resources Emergency Act HR 3797 Medical Marijuana Research Act of 2019

Client expense: $230,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institute on Alcohol Abuse & Alcoholism (NIAA), Natl Institutes of Health (NIH), Natl Science Foundation (NSF), Natl Security Agency (NSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)

H.R. 1949, 1950, 1951: Juvenile sentencing reform H.R. 494: Juvenile Accountability Block Grant Program H.R. 1585: Violence Against Women Reauthorization Act Draft legislation on incarcerated pregnant women S. 1983: CREATE Opportunities Act H.R. 3435: Local Public Health and Safety Act H.R. 838: Threat Assessment, Prevention, and Safety Act of 2019 H.R. 8: Bipartisan Background Checks Act of 2019 Draft Legislation on Extreme Risk Protection Orders HR 3539: Behavioral Intervention Guidelines Act of 2019

Client expense: $230,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institute on Alcohol Abuse & Alcoholism (NIAA), Natl Institutes of Health (NIH), Natl Science Foundation (NSF), Natl Security Agency (NSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)

The Special Registration for Telemedicine Clarification Act (H.R. 5483 (115)), all provisions related to establishing a special registration process with the Drug Enforcement Agency (DEA) for certain providers that wish to prescribe controlled substances via telemedicine. Mainstreaming Addiction Treatment Act (S. 2074/H.R. 2482), all provisions related to removing the waiver requirement for health care providers to prescribe buprenorphine for opioid use disorder. National Suicide Hotline Designation Act of 2019 (H.R. 4194), all provisions related to requiring the Federal Communications Commission designate 9-8-8 as a universal national suicide prevention and mental health crisis hotline number. Improving Access to Remote Behavioral Health Treatment Act of 2019 (S. 2244/H.R. 4131), all provisions related to amending regulations for the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 and allowing community mental health centers to register to practice telemedicine. Comprehensive Addiction Resources Emergency Act of 2019 (S. 1365/H.R. 2569), all provisions related to providing emergency assistance to areas affected by the opioid epidemic, as well as grant funding for substance use disorder treatment research. Mental Health Parity Compliance Act (S. 1737/H.R. 3165), all provisions related to strengthening parity for mental health and substance use disorder benefits. Effective Suicide Screening and Assessment in the Emergency Department Act of 2019 (S. 3006/H.R. 4861), all provisions related to establishing a program to improve identification, assessment, and treatment of patients in the emergency department who are at risk of suicide. Behavioral Health Coverage Transparency Act (S. 1576/H.R. 2874), all provisions related to strengthening parity for mental health and substance use disorder benefits. Medication Access and Training Expansion Act of 2019 (H.R. 4974), all provisions related to prescriber training on treating patients with opioid and other substance use disorders. Resilience Investment, Support and Expansion from Trauma Act (S. 1770/H.R. 3180), all provisions related to supporting children and families who experience trauma. Barriers to Suicide Act of 2019 (H.R. 4309), all provisions related to establishing a grant program to install suicide deterrents. Mental Health Professionals Workforce Shortage Loan Repayment Act of 2019 (S. 2500/H.R. 2431), all provisions related to authorizing a loan repayment program for mental health professionals. Parity Enforcement Act of 2019 (H.R. 2848), all provisions related to strengthening parity for mental health and substance use disorder benefits. Protecting Pre-Existing Conditions and Making Health Care More Affordable Act of 2019 (H.R. 1884), all provisions related to improving affordability of and increasing access to health insurance coverage. Mental Health Services for Students Act of 2019 (S. 1122), all provisions related to providing access to school-based comprehensive mental health programs. CREATE Opportunities Act (S. 1983/H.R. 3496), all provisions related to providing medication-assisted treatment to individuals with opioid use disorder and are incarcerated. Primary and Behavioral Health Care Access Act (H.R. 5575), all provisions related to requiring group health plans and health insurance issuers to provide for primary and behavioral health care visits without cost-sharing.

National De-Escalation of Violence and Community Safety Training Act (H.R. 2457), all provisions related to establishing a program allowing eligible entities such as churches, schools, community colleges, or state and local governments to provide de-escalation training to prevent and reduce violence in our communities, including the reauthorization of Mental Health First Aid training grants. CREATE Opportunities Act (S. 1983/H.R. 3496), all provisions related to expanding medication-assisted treatment for incarcerated individuals. Restoring, Enhancing, Securing, and Promoting Our Nations Safety Efforts (RESPONSE) Act of 2019 (S. 2690), all provisions related to strengthening mental health collaboration in communities.

Client expense: $68,150 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, SENATE

Issues surrounding cleanup standards for soil remediation at superfund sites and policies for encouraging faster clean up of superfund sites. Issues regarding use of ethylene oxide. Clean Industrial Technology Act (H.R. 3978, H.R. 4230, S. 2300). BASF supports CITA as a step to addressing climate change, by encouragint the development and evaluation of innovative technologies aimed at increasing the technological and economic competitiveness of industry and manufacturing in the US and increasing emissions reductions in non-power industrial sectors. Climate Change (no bills). BASF supports legislation on climate change that: ensure that reduction targets are economically feasible and technologically reasonable. Policies must allow energy-intensive and trade-exposed (EITE) companies to remain globally competitive (carbon leakage protection). Plastics, S. 1983, H.R. 5115, S. 2941: Save Our Seas Act 2.0 (BASF supports the bill and proposals for funding of advanced recylcling

Client expense: $280,000 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Supported S.1012/ HR 2062 Protecting Jessica Grubbs Legacy Act/ Overdose Prevention and Patient Safety Act to amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported HR 4974: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products Submitted comments on amendments to regulations under the Federal anti-kickback statute (AKS). The proposed amendments would modify and add new safe harbors under the statute and exceptions to the beneficiary inducements civil monetary penalty definition of remuneration to foster arrangements that would promote care coordination and advance the delivery of value-based care while also protecting patients and taxpayer dollars against harms caused by fraud and abuse. Supported H.Res. 714: Recognizing addiction as a disease and supporting efforts to prevent, treat, and destigmatize substance use disorder and addiction. Submitted a response to a request for information (RFI) regarding substance use disorder (SUD) treatment by Representatives Greg Walden, Michael Burgess, and Brett Guthrie, Republican leaders of the House Committee on Energy and Commerce. The RFI focused on challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment. Provided comments to ONDCP regarding next National Drug Control Strategy per invitation, focusing on addiction treatment workforce, setting standards, monitoring program effectiveness, coverage for addiction treatment services.

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Supported S.1012/ HR 2062 Protecting Jessica Grubbs Legacy Act/ Overdose Prevention and Patient Safety Act to amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported HR 4974: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products Submitted comments on amendments to regulations under the Federal anti-kickback statute (AKS). The proposed amendments would modify and add new safe harbors under the statute and exceptions to the beneficiary inducements civil monetary penalty definition of remuneration to foster arrangements that would promote care coordination and advance the delivery of value-based care while also protecting patients and taxpayer dollars against harms caused by fraud and abuse. Supported H.Res. 714: Recognizing addiction as a disease and supporting efforts to prevent, treat, and destigmatize substance use disorder and addiction. Submitted a response to a request for information (RFI) regarding substance use disorder (SUD) treatment by Representatives Greg Walden, Michael Burgess, and Brett Guthrie, Republican leaders of the House Committee on Energy and Commerce. The RFI focused on challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment. Provided comments to ONDCP regarding next National Drug Control Strategy per invitation, focusing on addiction treatment workforce, setting standards, monitoring program effectiveness, coverage for addiction treatment services.

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Supported S.1012/ HR 2062 Protecting Jessica Grubbs Legacy Act/ Overdose Prevention and Patient Safety Act to amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported HR 4974: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products Submitted comments on amendments to regulations under the Federal anti-kickback statute (AKS). The proposed amendments would modify and add new safe harbors under the statute and exceptions to the beneficiary inducements civil monetary penalty definition of remuneration to foster arrangements that would promote care coordination and advance the delivery of value-based care while also protecting patients and taxpayer dollars against harms caused by fraud and abuse. Supported H.Res. 714: Recognizing addiction as a disease and supporting efforts to prevent, treat, and destigmatize substance use disorder and addiction. Submitted a response to a request for information (RFI) regarding substance use disorder (SUD) treatment by Representatives Greg Walden, Michael Burgess, and Brett Guthrie, Republican leaders of the House Committee on Energy and Commerce. The RFI focused on challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment. Provided comments to ONDCP regarding next National Drug Control Strategy per invitation, focusing on addiction treatment workforce, setting standards, monitoring program effectiveness, coverage for addiction treatment services.

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Supported S.1012/ HR 2062 Protecting Jessica Grubbs Legacy Act/ Overdose Prevention and Patient Safety Act to amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported HR 4974: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products Submitted comments on amendments to regulations under the Federal anti-kickback statute (AKS). The proposed amendments would modify and add new safe harbors under the statute and exceptions to the beneficiary inducements civil monetary penalty definition of remuneration to foster arrangements that would promote care coordination and advance the delivery of value-based care while also protecting patients and taxpayer dollars against harms caused by fraud and abuse. Supported H.Res. 714: Recognizing addiction as a disease and supporting efforts to prevent, treat, and destigmatize substance use disorder and addiction. Submitted a response to a request for information (RFI) regarding substance use disorder (SUD) treatment by Representatives Greg Walden, Michael Burgess, and Brett Guthrie, Republican leaders of the House Committee on Energy and Commerce. The RFI focused on challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment. Provided comments to ONDCP regarding next National Drug Control Strategy per invitation, focusing on addiction treatment workforce, setting standards, monitoring program effectiveness, coverage for addiction treatment services.

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Supported S.1012/ HR 2062 Protecting Jessica Grubbs Legacy Act/ Overdose Prevention and Patient Safety Act to amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported HR 4974: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products Submitted comments on amendments to regulations under the Federal anti-kickback statute (AKS). The proposed amendments would modify and add new safe harbors under the statute and exceptions to the beneficiary inducements civil monetary penalty definition of remuneration to foster arrangements that would promote care coordination and advance the delivery of value-based care while also protecting patients and taxpayer dollars against harms caused by fraud and abuse. Supported H.Res. 714: Recognizing addiction as a disease and supporting efforts to prevent, treat, and destigmatize substance use disorder and addiction. Submitted a response to a request for information (RFI) regarding substance use disorder (SUD) treatment by Representatives Greg Walden, Michael Burgess, and Brett Guthrie, Republican leaders of the House Committee on Energy and Commerce. The RFI focused on challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment. Provided comments to ONDCP regarding next National Drug Control Strategy per invitation, focusing on addiction treatment workforce, setting standards, monitoring program effectiveness, coverage for addiction treatment services.

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Supported S.1012/ HR 2062 Protecting Jessica Grubbs Legacy Act/ Overdose Prevention and Patient Safety Act to amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported HR 4974: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products Submitted comments on amendments to regulations under the Federal anti-kickback statute (AKS). The proposed amendments would modify and add new safe harbors under the statute and exceptions to the beneficiary inducements civil monetary penalty definition of remuneration to foster arrangements that would promote care coordination and advance the delivery of value-based care while also protecting patients and taxpayer dollars against harms caused by fraud and abuse. Supported H.Res. 714: Recognizing addiction as a disease and supporting efforts to prevent, treat, and destigmatize substance use disorder and addiction. Submitted a response to a request for information (RFI) regarding substance use disorder (SUD) treatment by Representatives Greg Walden, Michael Burgess, and Brett Guthrie, Republican leaders of the House Committee on Energy and Commerce. The RFI focused on challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment. Provided comments to ONDCP regarding next National Drug Control Strategy per invitation, focusing on addiction treatment workforce, setting standards, monitoring program effectiveness, coverage for addiction treatment services.

Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020 (H.R. 2740); CREATE Opportunities Act (S. 1983).

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94)

Client expense: $950,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)

H.R. 1949, 1950, 1951: Juvenile sentencing reform H.R. 494: Juvenile Accountability Block Grant Program H.R. 1585: Violence Against Women Reauthorization Act Draft legislation on incarcerated pregnant women S. 1983: CREATE Opportunities Act H.R. 3435: Local Public Health and Safety Act H.R. 838: Threat Assessment, Prevention, and Safety Act of 2019 H.R. 8: Bipartisan Background Checks Act of 2019 Draft Legislation on Extreme Risk Protection Orders HR 3539: Behavioral Intervention Guidelines Act of 2019

Client expense: $200,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, Employment & Training Administration, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Natl Science Foundation (NSF), Natl Security Agency (NSA), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)

H.R. 3591: Campus Prevention and Recovery Services for Students Act of 2019 H.R. 2466: State Opioid Response Grant Authorization Act H.R. 2922: Respond Now Act H.R. 3489, S. 1204: Higher Education Mental Health Act of 2019 H.R. 3496, S. 1983: Create Opportunities Act H.R. 2569, S. 1365: Comprehensive Addiction Resources Emergency Act

Client expense: $200,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, Employment & Training Administration, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Natl Science Foundation (NSF), Natl Security Agency (NSA), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)

Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; FY2020 appropriations for Labor-HHS, CJS and Interior (Indian Health Service) bills; CREATE Opportunities Act (S. 1983/H.R. 3496)

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings H.J. Res 31, Consolidated Appropriations Act of 2019 (PL 116-6) H.J. Res 28, FY19 Further Additional Continuing Appropriation Act (PL 116-5) S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act HR 6 (PL 115-271) The Support Act funding, including Comprehensive Opioid Recovery Centers

Client expense: $790,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)

Cannabidiol and Marijuana Research Expansion Act H.R. 3591: Campus Prevention and Recovery Services for Students Act of 2019 H.R. 2466: State Opioid Response Grant Authorization Act H.R. 2922: Respond Now Act H.R. 3489, S. 1204: Higher Education Mental Health Act of 2019 H.R. 3496, S. 1983: Create Opportunities Act H.R. 2569, S. 1365: Comprehensive Addiction Resources Emergency Act

Client expense: $300,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institute on Alcohol Abuse & Alcoholism (NIAA), Natl Institutes of Health (NIH), Natl Science Foundation (NSF), Natl Security Agency (NSA), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

H.R. 1949, 1950, 1951: Juvenile sentencing reform H.R. 494: Juvenile Accountability Block Grant Program H.R. 1585: Violence Against Women Reauthorization Act Draft legislation on incarcerated pregnant women S. 1983: CREATE Opportunities Act H.R. 3435: Local Public Health and Safety Act H.R. 838: Threat Assessment, Prevention, and Safety Act of 2019 H.R. 8: Bipartisan Background Checks Act of 2019 Draft Legislation on Extreme Risk Protection Orders

Client expense: $300,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institute on Alcohol Abuse & Alcoholism (NIAA), Natl Institutes of Health (NIH), Natl Science Foundation (NSF), Natl Security Agency (NSA), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements. Discussions/comments regarding FY20 Medicare Physician Fee Schedule, particularly around OTP payment bundle and OUD demonstration payment codes Advocated for filing of the Medication Access and Training Expansion Act which would require every DEA controlled substance prescriber to satisfy an addiction medicine education requirement Submitted a letter in response to a request for comments from the Food and Drug Administration regarding data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds. ASAMs letter stressed the importance of conducting additional research on cannabis. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Issued a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Expanding Findings for Federal Opioid Research and Treatment (EFFORT) Act, sponsored by Representative Jennifer Wexton (D-VA) and Representative Jim Baird (R-IN). The bill would direct the National Science Foundation to support research on opioid use disorder. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Provided comments to SAMHSA's issuance of notices of proposed rulemaking (NPRM), Coordinating Care and Information Sharing in the Treatment of Substance Use Disorders, which would, among other things, modify and modernize 42 CFR Part 2, the regulations that govern confidentiality of drug and alcohol treatment and prevention records. The changes would strengthen the ability of healthcare providers to coordinate care for patients suffering from substance use disorder. Replied to the Request for Information: Ensuring Patient Access and Effective Drug Enforcement. In its comments, ASAM urged the DEA to investigate whether some of its policies were unintentionally decreasing access to buprenorphine. The letter also discussed opportunities for improved education of the medical community, and possible enhancements to state PDMPs. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Submitted comments on the 2020 Medicare Physician Fee Schedule Proposed Rule. In its comments, ASAM applauded the introduction of two bundled payment structures, one for outpatient treatment of OUD and one for OTPs. However, it also noted that the proposed reimbursement rates were significantly lower than necessary to expand access to MAT. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements. Discussions/comments regarding FY20 Medicare Physician Fee Schedule, particularly around OTP payment bundle and OUD demonstration payment codes Advocated for filing of the Medication Access and Training Expansion Act which would require every DEA controlled substance prescriber to satisfy an addiction medicine education requirement Submitted a letter in response to a request for comments from the Food and Drug Administration regarding data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds. ASAMs letter stressed the importance of conducting additional research on cannabis. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Issued a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Expanding Findings for Federal Opioid Research and Treatment (EFFORT) Act, sponsored by Representative Jennifer Wexton (D-VA) and Representative Jim Baird (R-IN). The bill would direct the National Science Foundation to support research on opioid use disorder. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Provided comments to SAMHSA's issuance of notices of proposed rulemaking (NPRM), Coordinating Care and Information Sharing in the Treatment of Substance Use Disorders, which would, among other things, modify and modernize 42 CFR Part 2, the regulations that govern confidentiality of drug and alcohol treatment and prevention records. The changes would strengthen the ability of healthcare providers to coordinate care for patients suffering from substance use disorder. Replied to the Request for Information: Ensuring Patient Access and Effective Drug Enforcement. In its comments, ASAM urged the DEA to investigate whether some of its policies were unintentionally decreasing access to buprenorphine. The letter also discussed opportunities for improved education of the medical community, and possible enhancements to state PDMPs. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Submitted comments on the 2020 Medicare Physician Fee Schedule Proposed Rule. In its comments, ASAM applauded the introduction of two bundled payment structures, one for outpatient treatment of OUD and one for OTPs. However, it also noted that the proposed reimbursement rates were significantly lower than necessary to expand access to MAT. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements. Discussions/comments regarding FY20 Medicare Physician Fee Schedule, particularly around OTP payment bundle and OUD demonstration payment codes Advocated for filing of the Medication Access and Training Expansion Act which would require every DEA controlled substance prescriber to satisfy an addiction medicine education requirement Submitted a letter in response to a request for comments from the Food and Drug Administration regarding data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds. ASAMs letter stressed the importance of conducting additional research on cannabis. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Issued a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Expanding Findings for Federal Opioid Research and Treatment (EFFORT) Act, sponsored by Representative Jennifer Wexton (D-VA) and Representative Jim Baird (R-IN). The bill would direct the National Science Foundation to support research on opioid use disorder. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Provided comments to SAMHSA's issuance of notices of proposed rulemaking (NPRM), Coordinating Care and Information Sharing in the Treatment of Substance Use Disorders, which would, among other things, modify and modernize 42 CFR Part 2, the regulations that govern confidentiality of drug and alcohol treatment and prevention records. The changes would strengthen the ability of healthcare providers to coordinate care for patients suffering from substance use disorder. Replied to the Request for Information: Ensuring Patient Access and Effective Drug Enforcement. In its comments, ASAM urged the DEA to investigate whether some of its policies were unintentionally decreasing access to buprenorphine. The letter also discussed opportunities for improved education of the medical community, and possible enhancements to state PDMPs. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Submitted comments on the 2020 Medicare Physician Fee Schedule Proposed Rule. In its comments, ASAM applauded the introduction of two bundled payment structures, one for outpatient treatment of OUD and one for OTPs. However, it also noted that the proposed reimbursement rates were significantly lower than necessary to expand access to MAT. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements. Discussions/comments regarding FY20 Medicare Physician Fee Schedule, particularly around OTP payment bundle and OUD demonstration payment codes Advocated for filing of the Medication Access and Training Expansion Act which would require every DEA controlled substance prescriber to satisfy an addiction medicine education requirement Submitted a letter in response to a request for comments from the Food and Drug Administration regarding data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds. ASAMs letter stressed the importance of conducting additional research on cannabis. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Issued a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Expanding Findings for Federal Opioid Research and Treatment (EFFORT) Act, sponsored by Representative Jennifer Wexton (D-VA) and Representative Jim Baird (R-IN). The bill would direct the National Science Foundation to support research on opioid use disorder. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Provided comments to SAMHSA's issuance of notices of proposed rulemaking (NPRM), Coordinating Care and Information Sharing in the Treatment of Substance Use Disorders, which would, among other things, modify and modernize 42 CFR Part 2, the regulations that govern confidentiality of drug and alcohol treatment and prevention records. The changes would strengthen the ability of healthcare providers to coordinate care for patients suffering from substance use disorder. Replied to the Request for Information: Ensuring Patient Access and Effective Drug Enforcement. In its comments, ASAM urged the DEA to investigate whether some of its policies were unintentionally decreasing access to buprenorphine. The letter also discussed opportunities for improved education of the medical community, and possible enhancements to state PDMPs. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Submitted comments on the 2020 Medicare Physician Fee Schedule Proposed Rule. In its comments, ASAM applauded the introduction of two bundled payment structures, one for outpatient treatment of OUD and one for OTPs. However, it also noted that the proposed reimbursement rates were significantly lower than necessary to expand access to MAT. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements. Discussions/comments regarding FY20 Medicare Physician Fee Schedule, particularly around OTP payment bundle and OUD demonstration payment codes Advocated for filing of the Medication Access and Training Expansion Act which would require every DEA controlled substance prescriber to satisfy an addiction medicine education requirement Submitted a letter in response to a request for comments from the Food and Drug Administration regarding data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds. ASAMs letter stressed the importance of conducting additional research on cannabis. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Issued a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Expanding Findings for Federal Opioid Research and Treatment (EFFORT) Act, sponsored by Representative Jennifer Wexton (D-VA) and Representative Jim Baird (R-IN). The bill would direct the National Science Foundation to support research on opioid use disorder. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Provided comments to SAMHSA's issuance of notices of proposed rulemaking (NPRM), Coordinating Care and Information Sharing in the Treatment of Substance Use Disorders, which would, among other things, modify and modernize 42 CFR Part 2, the regulations that govern confidentiality of drug and alcohol treatment and prevention records. The changes would strengthen the ability of healthcare providers to coordinate care for patients suffering from substance use disorder. Replied to the Request for Information: Ensuring Patient Access and Effective Drug Enforcement. In its comments, ASAM urged the DEA to investigate whether some of its policies were unintentionally decreasing access to buprenorphine. The letter also discussed opportunities for improved education of the medical community, and possible enhancements to state PDMPs. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Submitted comments on the 2020 Medicare Physician Fee Schedule Proposed Rule. In its comments, ASAM applauded the introduction of two bundled payment structures, one for outpatient treatment of OUD and one for OTPs. However, it also noted that the proposed reimbursement rates were significantly lower than necessary to expand access to MAT. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products

National De-Escalation of Violence and Community Safety Training Act (H.R. 2457), all provisions related to establishing a program allowing eligible entities such as churches, schools, community colleges, or state and local governments to provide de-escalation training to prevent and reduce violence in our communities, including the reauthorization of Mental Health First Aid training grants. CREATE Opportunities Act (S. 1983/H.R. 3496), all provisions related to expanding medication-assisted treatment for incarcerated individuals.

Client expense: $96,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, SENATE

Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings H.J. Res 31, Consolidated Appropriations Act of 2019 (PL 116-6) H.J. Res 28, FY19 Further Additional Continuing Appropriation Act (PL 116-5) S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act

Client expense: $640,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)

Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; FY2020 appropriations for Labor-HHS, CJS and Interior (Indian Health Service) bills; CREATE Opportunities Act (S. 1983/H.R. 3496)

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 2874 and S 1576 - Behavioral Health Coverage Transparency Act which would require issuers to disclose the analysis they perform in making parity determinations; require federal regulators to conduct random audits; and require the federal parity agencies to review denial rates for mental health versus medical claims. Additionally, it would create a central online portal so that people can access all information as a one-stop shop, and submit complaints and violations. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Joined members of the Mental Health Liaison Group (MHLG) and 25 other organizations in sending letters expressing support for the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Joined other organizations in sending a letter urging Members of Congress to support the Johns S. McCain Opioid Addiction Prevention Act (S. 724 / H.R. 1614). The legislation would limit initial opioid prescriptions for acute pain to 7 days. Supported S 1556 - No Junk Plans Act. This bill would legislatively block implementation of the Trump Administrations Short-Term, Limited Duration Insurance rule. This rule loosened restrictions on these plans, allowing enrollees to be on short-term plans for up to a year and renew their short-term plan for up to 3 years. Joined members of the Partnership to Amend 42 CFR Part 2 in sending a letter urging addition of the legislative language in S. 1012, the Protecting Jessica Grubbs Legacy Act to the Lower Health Care Costs Act of 2019. S. 1012 would align Part 2 with HIPAA for TPO, and strengthen protections against the use of addiction records in criminal, civil, or administrative proceedings. In addition, the bill further amplifies patient protections by incorporating antidiscrimination language, significantly enhancing penalties for any breach of a persons substance use record, and adding breach notification requirements. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Joined the Friends of NIDA in sending a letter in support of the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Provided technical assistance and support for new legislation requiring all controlled substance prescribers with a DEA license to become DATA 2000 waiver trained Joined over 75 organizations in sending a letter urging members of Congress to cosponsor The Resident Physician Shortage Reduction Act of 2019 (S.348, H.R. 1763), which would increase the number of residency positions funded by Medicare in hospitals around the country by 15,000 over 5 years. This legislation would work to expand the physician workforce to address alarming projected deficits of physicians in both primary and specialty care. Joined members of the Mental Health Liaison Group (MHLG) in sending a letter to the leadership of the House Committee on Budget in support of H.R. 2021 - the Investing for the People Act of 2019. This legislation would raise both the defense and nondefense discretionary caps by $88 billion each in Fiscal Years 2020 and 2021. Joined members of the Tobacco Partners Coalition in sending a letter in response to a request for comment issued by the Food and Drug Administration. The request for comment seeks industry input regarding draft guidance being developed by the FDA on modifications to compliance policy for certain deemed tobacco products. Joined members of the Mental Health Liason Group (MHLG) in sending a letter voicing support for H.R. 1329, the Medicaid Reentry Act. The bill would work to grant Medicaid eligibility to incarcerated individuals 30-days prior to their release. The Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 would exempt some cigars, including some inexpensive, machine-made cigars, from FDA oversight. Advocated that FDA rightly concluded in the final Deeming Rule that there was no public health justification for exempting any cigars from FDA oversight because all cigars pose significant health risks. One difference this year is that the House added language specifying that cigars with flavor additives would not fit the bills definition of a premium cigar. Despite the flavors language, the bill would still exempt some cheap, machine-made cigars that youth are using from FDA oversight. The Senate bill did not include language on flavors. Supported The Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act) is legislation that would curb the use of flavors in tobacco products, including e-cigarettes and cigars. Supported introduction of legislation to make the Veterans Health Administration (VHA) facilities smoke-free. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements Provided technical assistance regarding Senator Shaheen's Turn the Tide Act which would increase funding to combat the addiction crisis, including efforts to stregthenen the addiction treatment workforce and increase Medicaid reimbursement for addiction treatment providers

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 2874 and S 1576 - Behavioral Health Coverage Transparency Act which would require issuers to disclose the analysis they perform in making parity determinations; require federal regulators to conduct random audits; and require the federal parity agencies to review denial rates for mental health versus medical claims. Additionally, it would create a central online portal so that people can access all information as a one-stop shop, and submit complaints and violations. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Joined members of the Mental Health Liaison Group (MHLG) and 25 other organizations in sending letters expressing support for the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Joined other organizations in sending a letter urging Members of Congress to support the Johns S. McCain Opioid Addiction Prevention Act (S. 724 / H.R. 1614). The legislation would limit initial opioid prescriptions for acute pain to 7 days. Supported S 1556 - No Junk Plans Act. This bill would legislatively block implementation of the Trump Administrations Short-Term, Limited Duration Insurance rule. This rule loosened restrictions on these plans, allowing enrollees to be on short-term plans for up to a year and renew their short-term plan for up to 3 years. Joined members of the Partnership to Amend 42 CFR Part 2 in sending a letter urging addition of the legislative language in S. 1012, the Protecting Jessica Grubbs Legacy Act to the Lower Health Care Costs Act of 2019. S. 1012 would align Part 2 with HIPAA for TPO, and strengthen protections against the use of addiction records in criminal, civil, or administrative proceedings. In addition, the bill further amplifies patient protections by incorporating antidiscrimination language, significantly enhancing penalties for any breach of a persons substance use record, and adding breach notification requirements. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Joined the Friends of NIDA in sending a letter in support of the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Provided technical assistance and support for new legislation requiring all controlled substance prescribers with a DEA license to become DATA 2000 waiver trained Joined over 75 organizations in sending a letter urging members of Congress to cosponsor The Resident Physician Shortage Reduction Act of 2019 (S.348, H.R. 1763), which would increase the number of residency positions funded by Medicare in hospitals around the country by 15,000 over 5 years. This legislation would work to expand the physician workforce to address alarming projected deficits of physicians in both primary and specialty care. Joined members of the Mental Health Liaison Group (MHLG) in sending a letter to the leadership of the House Committee on Budget in support of H.R. 2021 - the Investing for the People Act of 2019. This legislation would raise both the defense and nondefense discretionary caps by $88 billion each in Fiscal Years 2020 and 2021. Joined members of the Tobacco Partners Coalition in sending a letter in response to a request for comment issued by the Food and Drug Administration. The request for comment seeks industry input regarding draft guidance being developed by the FDA on modifications to compliance policy for certain deemed tobacco products. Joined members of the Mental Health Liason Group (MHLG) in sending a letter voicing support for H.R. 1329, the Medicaid Reentry Act. The bill would work to grant Medicaid eligibility to incarcerated individuals 30-days prior to their release. The Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 would exempt some cigars, including some inexpensive, machine-made cigars, from FDA oversight. Advocated that FDA rightly concluded in the final Deeming Rule that there was no public health justification for exempting any cigars from FDA oversight because all cigars pose significant health risks. One difference this year is that the House added language specifying that cigars with flavor additives would not fit the bills definition of a premium cigar. Despite the flavors language, the bill would still exempt some cheap, machine-made cigars that youth are using from FDA oversight. The Senate bill did not include language on flavors. Supported The Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act) is legislation that would curb the use of flavors in tobacco products, including e-cigarettes and cigars. Supported introduction of legislation to make the Veterans Health Administration (VHA) facilities smoke-free. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements Provided technical assistance regarding Senator Shaheen's Turn the Tide Act which would increase funding to combat the addiction crisis, including efforts to stregthenen the addiction treatment workforce and increase Medicaid reimbursement for addiction treatment providers

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 2874 and S 1576 - Behavioral Health Coverage Transparency Act which would require issuers to disclose the analysis they perform in making parity determinations; require federal regulators to conduct random audits; and require the federal parity agencies to review denial rates for mental health versus medical claims. Additionally, it would create a central online portal so that people can access all information as a one-stop shop, and submit complaints and violations. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Joined members of the Mental Health Liaison Group (MHLG) and 25 other organizations in sending letters expressing support for the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Joined other organizations in sending a letter urging Members of Congress to support the Johns S. McCain Opioid Addiction Prevention Act (S. 724 / H.R. 1614). The legislation would limit initial opioid prescriptions for acute pain to 7 days. Supported S 1556 - No Junk Plans Act. This bill would legislatively block implementation of the Trump Administrations Short-Term, Limited Duration Insurance rule. This rule loosened restrictions on these plans, allowing enrollees to be on short-term plans for up to a year and renew their short-term plan for up to 3 years. Joined members of the Partnership to Amend 42 CFR Part 2 in sending a letter urging addition of the legislative language in S. 1012, the Protecting Jessica Grubbs Legacy Act to the Lower Health Care Costs Act of 2019. S. 1012 would align Part 2 with HIPAA for TPO, and strengthen protections against the use of addiction records in criminal, civil, or administrative proceedings. In addition, the bill further amplifies patient protections by incorporating antidiscrimination language, significantly enhancing penalties for any breach of a persons substance use record, and adding breach notification requirements. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Joined the Friends of NIDA in sending a letter in support of the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Provided technical assistance and support for new legislation requiring all controlled substance prescribers with a DEA license to become DATA 2000 waiver trained Joined over 75 organizations in sending a letter urging members of Congress to cosponsor The Resident Physician Shortage Reduction Act of 2019 (S.348, H.R. 1763), which would increase the number of residency positions funded by Medicare in hospitals around the country by 15,000 over 5 years. This legislation would work to expand the physician workforce to address alarming projected deficits of physicians in both primary and specialty care. Joined members of the Mental Health Liaison Group (MHLG) in sending a letter to the leadership of the House Committee on Budget in support of H.R. 2021 - the Investing for the People Act of 2019. This legislation would raise both the defense and nondefense discretionary caps by $88 billion each in Fiscal Years 2020 and 2021. Joined members of the Tobacco Partners Coalition in sending a letter in response to a request for comment issued by the Food and Drug Administration. The request for comment seeks industry input regarding draft guidance being developed by the FDA on modifications to compliance policy for certain deemed tobacco products. Joined members of the Mental Health Liason Group (MHLG) in sending a letter voicing support for H.R. 1329, the Medicaid Reentry Act. The bill would work to grant Medicaid eligibility to incarcerated individuals 30-days prior to their release. The Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 would exempt some cigars, including some inexpensive, machine-made cigars, from FDA oversight. Advocated that FDA rightly concluded in the final Deeming Rule that there was no public health justification for exempting any cigars from FDA oversight because all cigars pose significant health risks. One difference this year is that the House added language specifying that cigars with flavor additives would not fit the bills definition of a premium cigar. Despite the flavors language, the bill would still exempt some cheap, machine-made cigars that youth are using from FDA oversight. The Senate bill did not include language on flavors. Supported The Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act) is legislation that would curb the use of flavors in tobacco products, including e-cigarettes and cigars. Supported introduction of legislation to make the Veterans Health Administration (VHA) facilities smoke-free. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements Provided technical assistance regarding Senator Shaheen's Turn the Tide Act which would increase funding to combat the addiction crisis, including efforts to stregthenen the addiction treatment workforce and increase Medicaid reimbursement for addiction treatment providers

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 2874 and S 1576 - Behavioral Health Coverage Transparency Act which would require issuers to disclose the analysis they perform in making parity determinations; require federal regulators to conduct random audits; and require the federal parity agencies to review denial rates for mental health versus medical claims. Additionally, it would create a central online portal so that people can access all information as a one-stop shop, and submit complaints and violations. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Joined members of the Mental Health Liaison Group (MHLG) and 25 other organizations in sending letters expressing support for the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Joined other organizations in sending a letter urging Members of Congress to support the Johns S. McCain Opioid Addiction Prevention Act (S. 724 / H.R. 1614). The legislation would limit initial opioid prescriptions for acute pain to 7 days. Supported S 1556 - No Junk Plans Act. This bill would legislatively block implementation of the Trump Administrations Short-Term, Limited Duration Insurance rule. This rule loosened restrictions on these plans, allowing enrollees to be on short-term plans for up to a year and renew their short-term plan for up to 3 years. Joined members of the Partnership to Amend 42 CFR Part 2 in sending a letter urging addition of the legislative language in S. 1012, the Protecting Jessica Grubbs Legacy Act to the Lower Health Care Costs Act of 2019. S. 1012 would align Part 2 with HIPAA for TPO, and strengthen protections against the use of addiction records in criminal, civil, or administrative proceedings. In addition, the bill further amplifies patient protections by incorporating antidiscrimination language, significantly enhancing penalties for any breach of a persons substance use record, and adding breach notification requirements. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Joined the Friends of NIDA in sending a letter in support of the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Provided technical assistance and support for new legislation requiring all controlled substance prescribers with a DEA license to become DATA 2000 waiver trained Joined over 75 organizations in sending a letter urging members of Congress to cosponsor The Resident Physician Shortage Reduction Act of 2019 (S.348, H.R. 1763), which would increase the number of residency positions funded by Medicare in hospitals around the country by 15,000 over 5 years. This legislation would work to expand the physician workforce to address alarming projected deficits of physicians in both primary and specialty care. Joined members of the Mental Health Liaison Group (MHLG) in sending a letter to the leadership of the House Committee on Budget in support of H.R. 2021 - the Investing for the People Act of 2019. This legislation would raise both the defense and nondefense discretionary caps by $88 billion each in Fiscal Years 2020 and 2021. Joined members of the Tobacco Partners Coalition in sending a letter in response to a request for comment issued by the Food and Drug Administration. The request for comment seeks industry input regarding draft guidance being developed by the FDA on modifications to compliance policy for certain deemed tobacco products. Joined members of the Mental Health Liason Group (MHLG) in sending a letter voicing support for H.R. 1329, the Medicaid Reentry Act. The bill would work to grant Medicaid eligibility to incarcerated individuals 30-days prior to their release. The Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 would exempt some cigars, including some inexpensive, machine-made cigars, from FDA oversight. Advocated that FDA rightly concluded in the final Deeming Rule that there was no public health justification for exempting any cigars from FDA oversight because all cigars pose significant health risks. One difference this year is that the House added language specifying that cigars with flavor additives would not fit the bills definition of a premium cigar. Despite the flavors language, the bill would still exempt some cheap, machine-made cigars that youth are using from FDA oversight. The Senate bill did not include language on flavors. Supported The Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act) is legislation that would curb the use of flavors in tobacco products, including e-cigarettes and cigars. Supported introduction of legislation to make the Veterans Health Administration (VHA) facilities smoke-free. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements Provided technical assistance regarding Senator Shaheen's Turn the Tide Act which would increase funding to combat the addiction crisis, including efforts to stregthenen the addiction treatment workforce and increase Medicaid reimbursement for addiction treatment providers

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 2874 and S 1576 - Behavioral Health Coverage Transparency Act which would require issuers to disclose the analysis they perform in making parity determinations; require federal regulators to conduct random audits; and require the federal parity agencies to review denial rates for mental health versus medical claims. Additionally, it would create a central online portal so that people can access all information as a one-stop shop, and submit complaints and violations. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Joined members of the Mental Health Liaison Group (MHLG) and 25 other organizations in sending letters expressing support for the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Joined other organizations in sending a letter urging Members of Congress to support the Johns S. McCain Opioid Addiction Prevention Act (S. 724 / H.R. 1614). The legislation would limit initial opioid prescriptions for acute pain to 7 days. Supported S 1556 - No Junk Plans Act. This bill would legislatively block implementation of the Trump Administrations Short-Term, Limited Duration Insurance rule. This rule loosened restrictions on these plans, allowing enrollees to be on short-term plans for up to a year and renew their short-term plan for up to 3 years. Joined members of the Partnership to Amend 42 CFR Part 2 in sending a letter urging addition of the legislative language in S. 1012, the Protecting Jessica Grubbs Legacy Act to the Lower Health Care Costs Act of 2019. S. 1012 would align Part 2 with HIPAA for TPO, and strengthen protections against the use of addiction records in criminal, civil, or administrative proceedings. In addition, the bill further amplifies patient protections by incorporating antidiscrimination language, significantly enhancing penalties for any breach of a persons substance use record, and adding breach notification requirements. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Joined the Friends of NIDA in sending a letter in support of the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Provided technical assistance and support for new legislation requiring all controlled substance prescribers with a DEA license to become DATA 2000 waiver trained Joined over 75 organizations in sending a letter urging members of Congress to cosponsor The Resident Physician Shortage Reduction Act of 2019 (S.348, H.R. 1763), which would increase the number of residency positions funded by Medicare in hospitals around the country by 15,000 over 5 years. This legislation would work to expand the physician workforce to address alarming projected deficits of physicians in both primary and specialty care. Joined members of the Mental Health Liaison Group (MHLG) in sending a letter to the leadership of the House Committee on Budget in support of H.R. 2021 - the Investing for the People Act of 2019. This legislation would raise both the defense and nondefense discretionary caps by $88 billion each in Fiscal Years 2020 and 2021. Joined members of the Tobacco Partners Coalition in sending a letter in response to a request for comment issued by the Food and Drug Administration. The request for comment seeks industry input regarding draft guidance being developed by the FDA on modifications to compliance policy for certain deemed tobacco products. Joined members of the Mental Health Liason Group (MHLG) in sending a letter voicing support for H.R. 1329, the Medicaid Reentry Act. The bill would work to grant Medicaid eligibility to incarcerated individuals 30-days prior to their release. The Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 would exempt some cigars, including some inexpensive, machine-made cigars, from FDA oversight. Advocated that FDA rightly concluded in the final Deeming Rule that there was no public health justification for exempting any cigars from FDA oversight because all cigars pose significant health risks. One difference this year is that the House added language specifying that cigars with flavor additives would not fit the bills definition of a premium cigar. Despite the flavors language, the bill would still exempt some cheap, machine-made cigars that youth are using from FDA oversight. The Senate bill did not include language on flavors. Supported The Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act) is legislation that would curb the use of flavors in tobacco products, including e-cigarettes and cigars. Supported introduction of legislation to make the Veterans Health Administration (VHA) facilities smoke-free. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements Provided technical assistance regarding Senator Shaheen's Turn the Tide Act which would increase funding to combat the addiction crisis, including efforts to stregthenen the addiction treatment workforce and increase Medicaid reimbursement for addiction treatment providers

Cannabidiol and Marijuana Research Expansion Act Medical Marijuana Research Act H.R. 3591: Campus Prevention and Recovery Services for Students Act of 2019 H.R. 2466: State Opioid Response Grant Authorization Act H.R. 2922: Respond Now Act H.R. 3489, S. 1204: Higher Education Mental Health Act of 2019 H.R. 3496, S. 1983: Create Opportunities Act H.R. 2569, S. 1365: Comprehensive Addiction Resources Emergency Act

Client expense: $280,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Natl Science Foundation (NSF), Natl Security Agency (NSA), SENATE

H.R. 1949, 1950, 1951: Juvenile sentencing reform H.R. 494: Juvenile Accountability Block Grant Program H.R. 1585: Violence Against Women Reauthorization Act Draft legislation on incarcerated pregnant women S. 1983: CREATE Opportunities Act H.R. 3435: Local Public Health and Safety Act H.R. 838: Threat Assessment, Prevention, and Safety Act of 2019

Client expense: $280,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Natl Science Foundation (NSF), Natl Security Agency (NSA), SENATE